OncoSec Medical Incorporated (ONCSQ) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerOncoSec Medical Incorporated (ONCSQ) trades at $0.00001. OncoSec Medical Incorporated is a late-stage immuno-oncology company focused on developing DNA-based therapeutics for cancer treatment. The company filed for liquidation under Chapter 7 bankruptcy in June 2023. Sector: Healthcare.
Price as of Sep 10, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ONCSQ: ONCSQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ONCSQ against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ONCSQ: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
OncoSec Medical Incorporated (ONCSQ) Healthcare & Pipeline Overview
OncoSec Medical Incorporated, an immuno-oncology company, focused on intra-tumoral DNA-based therapeutics to stimulate anti-tumor immune responses. Despite clinical trial collaborations with Merck and Duke University, the company filed for Chapter 7 liquidation in 2023, impacting its pipeline of cancer treatments and COVID-19 therapies. The company's stock trades on the OTC market.
What Is the Investment Thesis for ONCSQ?
OncoSec Medical Incorporated's Chapter 7 liquidation filing in June 2023 represents a significant event for investors. The company's pipeline, which included multiple Phase 1 and Phase 2 clinical trials, is now subject to the bankruptcy proceedings. Key collaborations with Merck and Duke University are unlikely to continue. The company's market capitalization was $0.00B prior to liquidation. The high beta of 9.96 indicates extreme volatility, which is now largely irrelevant given the bankruptcy. Investors should be aware that recovery on OTC stocks after bankruptcy is highly uncertain.
Based on FMP financials and quantitative analysis
ONCSQ Key Highlights
OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
- The company's market capitalization was $0.00B prior to liquidation.
- The company's pipeline included multiple Phase 1 and Phase 2 clinical trials targeting various cancers and COVID-19.
- OncoSec had clinical trial collaborations with Merck & Co., Inc. and research collaboration with Duke University.
- The stock trades on the OTC market, specifically the OTC Other tier.
Who Are ONCSQ's Competitors?
ONCSQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.84% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.77 | -3.37% | $320M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | 885-pillar |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | 875-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are ONCSQ's Key Strengths?
Proprietary DNA-based therapeutic technology.
- Clinical trial collaborations with established institutions.
- Diverse pipeline of immuno-oncology treatments.
What Are ONCSQ's Weaknesses?
Chapter 7 liquidation filing.
- Dependence on collaborations for funding.
- High risk of clinical trial failure.
What Could Drive ONCSQ Stock Higher?
OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
What Are the Key Risks for ONCSQ?
Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 5 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Chapter 7 bankruptcy proceedings.
- Loss of intellectual property.
- Inability to continue clinical trials.
- Legal claims from creditors.
- Delisting from the OTC market.
What Are the Growth Opportunities for ONCSQ?
- OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
What Opportunities Does ONCSQ Have?
- N/A due to liquidation filing.
What Are ONCSQ's Competitive Advantages?
- Proprietary intra-tumoral DNA-based therapeutic technology.
- Clinical trial collaborations with Merck & Co., Inc. and Duke University.
- Pipeline of Phase 1 and Phase 2 clinical trials.
What Does ONCSQ Do?
OncoSec Medical Incorporated, formerly known as NetVentory Solutions Inc., was founded in 2008 and rebranded in March 2011 to focus on immuno-oncology. Headquartered in Pennington, New Jersey, the company specialized in designing, developing, and commercializing intra-tumoral DNA-based therapeutics aimed at stimulating and augmenting anti-tumor immune responses for cancer treatment. Their product pipeline included KEYNOTE-695, a Phase 2 trial for advanced melanoma, and TAVO + SARS-CoV-2 spike glycoprotein, a Phase 1 clinical trial for COVID-19. Additional trials included TAVO + epacadostat + pembrolizumab for squamous cell carcinoma of the head and neck, TAVO + nivolumab for breast cancer, and TAVO + CXCL9 for solid tumors, along with OMS-100 and OMS-102 for metastatic melanoma. OncoSec collaborated with Merck & Co., Inc. on KEYNOTE-695 and KEYNOTE-890 and with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination with a HER2-plasmid vaccine. However, on June 14, 2023, OncoSec filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey, ceasing its operations and development programs.
What Products and Services Does ONCSQ Offer?
- Developed intra-tumoral DNA-based therapeutics.
- Focused on stimulating anti-tumor immune responses.
- Conducted Phase 1 and Phase 2 clinical trials for cancer treatments.
- Developed a COVID-19 therapy in Phase 1 clinical trial.
- Collaborated with Merck & Co., Inc. on clinical trials.
- Partnered with Duke University for research.
How Does ONCSQ Make Money?
- Focused on developing and commercializing immuno-oncology therapeutics.
- Generated revenue through potential future sales of approved therapies.
- Relied on collaborations and partnerships for funding and clinical trials.
What Industry Does ONCSQ Operate In?
OncoSec Medical Incorporated operated within the competitive biotechnology industry, focusing on immuno-oncology. This sector involves developing therapies that harness the body's immune system to fight cancer. The industry is characterized by high research and development costs, lengthy clinical trial processes, and regulatory hurdles. Companies like OncoSec often collaborate with larger pharmaceutical firms to fund and conduct clinical trials. The failure rate for biotechnology companies is high, and OncoSec's bankruptcy reflects the challenges inherent in bringing novel therapies to market. Competitors focus on similar immuno-oncology approaches, creating a crowded and dynamic landscape.
Who Are ONCSQ's Key Customers?
- Patients with advanced melanoma.
- Patients with squamous cell carcinoma of the head and neck.
- Patients with breast cancer.
- Patients with solid tumors.
- Patients with COVID-19.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 52 |
| 2026-08-26 | 52 |
| 2026-08-29 | 52 |
| 2026-09-01 | 52 |
| 2026-09-04 | 52 |
| 2026-09-07 | 52 |
| 2026-09-10 | 52 |
What changed?
The score has stayed at 52.
Over the same 18 days the stock moved +0.0%.
Company Profile
OncoSec Medical Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pennington, US. ONCSQ has traded publicly since 2010.
Financial Health
OncoSec Medical Incorporated's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
OncoSec Medical Incorporated has missed Wall Street's EPS estimate in 2 of its last 5 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 164.4% below estimates on average.
Forward Outlook
Wall Street analysts project OncoSec Medical Incorporated revenue of about $298.5M for fiscal 2026, with EPS near $64.02.
ONCSQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary DNA-based therapeutic technology.
- Clinical trial collaborations with established institutions.
- Diverse pipeline of immuno-oncology treatments.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
Bear Case
- Chapter 7 liquidation filing.
- Dependence on collaborations for funding.
- High risk of clinical trial failure.
- Ongoing: Chapter 7 bankruptcy proceedings.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ONCSQ Latest News
No recent news available for ONCSQ.
ONCSQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ONCSQ.
Price Targets
Wall Street price target analysis for ONCSQ.
ONCSQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ONCSQ; grades run from A+ (80-100) to F (below 30).
ONCSQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to provide current information to the market. These securities often include companies in bankruptcy, those with regulatory issues, or those that are thinly traded. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and limited financial disclosure compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low liquidity and wide bid-ask spreads.
- Potential for fraud or manipulation.
- Bankruptcy risk.
- Lack of regulatory oversight.
- Verify the company's bankruptcy status with the U.S. Bankruptcy Court.
- Attempt to locate any available financial statements.
- Assess the trading volume and bid-ask spread.
- Consult with a financial advisor.
- Understand the risks associated with OTC Other stocks.
- Determine the potential for recovery in bankruptcy proceedings.
- Research the company's assets and liabilities.
- Prior clinical trial collaborations with Merck & Co., Inc. and Duke University.
- Previous focus on developing immuno-oncology therapies.
- Listing on the OTC market, despite the bankruptcy.
Common Questions About ONCSQ (Healthcare)
Is ONCSQ a good stock?
Stock Expert AI does not rate ONCSQ buy, sell or hold. OncoSec Medical Incorporated has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for ONCSQ?
The primary risk for ONCSQ is the Chapter 7 bankruptcy filing, which indicates that the company is undergoing liquidation. This means that the company's assets will be sold to pay off creditors, and there is a high likelihood that shareholders will receive little to no recovery.
What are the key factors to evaluate for ONCSQ?
Evaluate ONCSQ on fundamentals, analyst consensus, and risk factors. The company's pipeline, which included multiple Phase 1 and Phase 2 clinical trials, is now subject to the bankruptcy proceedings. Not financial advice.
How frequently does ONCSQ data refresh on this page?
ONCSQ's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ONCSQ's recent stock price performance?
OncoSec Medical Incorporated (ONCSQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary DNA-based therapeutic technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ONCSQ overvalued or undervalued right now?
OncoSec Medical Incorporated (ONCSQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ONCSQ?
Yes, most major brokerages offer fractional shares of OncoSec Medical Incorporated (ONCSQ) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ONCSQ's earnings and financial reports?
OncoSec Medical Incorporated (ONCSQ) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ONCSQ earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change due to the ongoing bankruptcy proceedings.